Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report)’s share price rose 1.5% during trading on Monday . The stock traded as high as $5.01 and last traded at $4.78. Approximately 635,796 shares were traded during trading, an increase of 88% from the average daily volume of 337,931 shares. The stock had previously closed at $4.71.
Silverback Therapeutics Stock Up 1.5 %
The company has a 50-day moving average of $4.25 and a 200 day moving average of $5.94. The firm has a market capitalization of $172.36 million, a PE ratio of -1.98 and a beta of 0.60.
Institutional Investors Weigh In On Silverback Therapeutics
Several hedge funds have recently bought and sold shares of SBTX. Sectoral Asset Management Inc. raised its position in shares of Silverback Therapeutics by 1.4% during the 1st quarter. Sectoral Asset Management Inc. now owns 793,587 shares of the company’s stock valued at $5,166,000 after buying an additional 11,177 shares in the last quarter. Royce & Associates LP purchased a new stake in Silverback Therapeutics during the first quarter valued at about $1,978,000. Virtu Financial LLC bought a new stake in Silverback Therapeutics during the first quarter worth about $68,000. Boothbay Fund Management LLC purchased a new position in shares of Silverback Therapeutics in the 4th quarter worth about $99,000. Finally, AQR Capital Management LLC increased its position in shares of Silverback Therapeutics by 81.2% during the 2nd quarter. AQR Capital Management LLC now owns 19,845 shares of the company’s stock valued at $84,000 after purchasing an additional 8,896 shares during the last quarter. 74.89% of the stock is currently owned by institutional investors.
Silverback Therapeutics Company Profile
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Featured Articles
- Five stocks we like better than Silverback Therapeutics
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- The most upgraded stocks in November have two things in common
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Monday.com rocked earnings like it’s the weekend
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
